Indantadol (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Indantadol" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

610^th place

653^rd place

2web.archive.org

1^st place

1^st place

low place

low place

low place

3,674^th place

1aspetjournals.org

6,663^rd place

3,586^th place

6^th place

5^th place

archive.org

Barbieri M; Bregola G; Buzzi A; et al. (2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology. 139 (7): 1333—41. PMC 1573965 . PMID 12890713. doi:10.1038/sj.bjp.0705381.

aspetjournals.org

jpet.aspetjournals.org

Villetti G; Bergamaschi M; Bassani F; et al. (2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 804—14. PMID 12750440. doi:10.1124/jpet.103.050039.

doi.org

Villetti G; Bregola G; Bassani F; et al. (2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology. 40 (7): 866—78. PMID 11378157. doi:10.1016/S0028-3908(01)00026-0.
Gandolfi O; Bonfante V; Voltattorni M; et al. (2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior. 70 (1): 157—66. PMID 11566153. doi:10.1016/S0091-3057(01)00591-3.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport. 13 (16): 2071—4. PMID 12438928. doi:10.1097/00001756-200211150-00016.
Villetti G; Bergamaschi M; Bassani F; et al. (2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 804—14. PMID 12750440. doi:10.1124/jpet.103.050039.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain. 7 (8): 565—74. PMID 16885013. doi:10.1016/j.jpain.2006.02.004.
Barbieri M; Bregola G; Buzzi A; et al. (2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology. 139 (7): 1333—41. PMC 1573965 . PMID 12890713. doi:10.1038/sj.bjp.0705381.

elsevier.com

linkinghub.elsevier.com

Villetti G; Bregola G; Bassani F; et al. (2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology. 40 (7): 866—78. PMID 11378157. doi:10.1016/S0028-3908(01)00026-0.
Gandolfi O; Bonfante V; Voltattorni M; et al. (2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior. 70 (1): 157—66. PMID 11566153. doi:10.1016/S0091-3057(01)00591-3.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain. 7 (8): 565—74. PMID 16885013. doi:10.1016/j.jpain.2006.02.004.

nih.gov

ncbi.nlm.nih.gov

Villetti G; Bregola G; Bassani F; et al. (2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology. 40 (7): 866—78. PMID 11378157. doi:10.1016/S0028-3908(01)00026-0.
Gandolfi O; Bonfante V; Voltattorni M; et al. (2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior. 70 (1): 157—66. PMID 11566153. doi:10.1016/S0091-3057(01)00591-3.
Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport. 13 (16): 2071—4. PMID 12438928. doi:10.1097/00001756-200211150-00016.
Villetti G; Bergamaschi M; Bassani F; et al. (2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 804—14. PMID 12750440. doi:10.1124/jpet.103.050039.
„CHF 3381”. Drugs in R&D. 5 (1): 28—30. 2004. PMID 14725488.
Mattia C, Coluzzi F (2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal. 10 (9): 636—44. PMID 17786847.
Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain. 7 (8): 565—74. PMID 16885013. doi:10.1016/j.jpain.2006.02.004.
Barbieri M; Bregola G; Buzzi A; et al. (2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology. 139 (7): 1333—41. PMC 1573965 . PMID 12890713. doi:10.1038/sj.bjp.0705381.

vernalis.com

„IN-STEP Phase IIb study results”. Архивирано из оригинала 13. 08. 2014. г.
„Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Архивирано из оригинала 13. 08. 2014. г.

web.archive.org

„IN-STEP Phase IIb study results”. Архивирано из оригинала 13. 08. 2014. г.
„Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Архивирано из оригинала 13. 08. 2014. г.

wkhealth.com

meta.wkhealth.com

Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport. 13 (16): 2071—4. PMID 12438928. doi:10.1097/00001756-200211150-00016.